|View printer-friendly version|$1.56 MillionAward
- Accelerates Retinal Restoration Program
“This grant is a significant validation of our vision restoration program from the NIH, which funds research and development that they believe has a strong potential for technology commercialization,” said
BioTime scientists have grown a piece of 3-dimensional (3-D) retinal tissue using the Company’s proprietary pluripotent cell technology platform. The 3-D retinal tissue contains all the cell types that comprise the human retina, including retinal pigment epithelium cells, photoreceptors and ganglion cells. Data presented at ARVO demonstrates that BioTime’s 3-D retinal tissue closely resembles a developing human retina. The technology may ultimately be used to repair and restore sections of degenerated retinal tissue to improve vision caused by retinal degeneration and traumatic injury. The Company’s 3-D retinal tissue technology may address the unmet need of implementing a retinal restoration strategy to address severe retinal degenerative diseases, with a mutation-free retinal tissue produced in a strictly controlled laboratory setting.
This vision restoration program will be a collaborative effort led by BioTime’s Principal Investigator Igor O. Nasonkin Ph.D., with Dr.
BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on Twitter, LinkedIn,
To receive ongoing
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for